PureTech Health (LON:PRTC) Stock Price Breaks Below 50 Day Moving Average – Here’s Why

PureTech Health plc (LON:PRTC)’s stock price crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of GBX 119.61 and traded as low as GBX 114.20. PureTech Health shares last traded at GBX 115, with a volume of 5,954,008 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 508 price target on shares of PureTech Health in a research report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of GBX 508.

PureTech Health Stock Down 2.5%

The firm’s 50-day simple moving average is GBX 119.36 and its 200-day simple moving average is GBX 123.60. The company has a debt-to-equity ratio of 4.78, a quick ratio of 2.51 and a current ratio of 4.60. The company has a market capitalization of £264.30 million, a price-to-earnings ratio of -2.34 and a beta of 0.77.

Insiders Place Their Bets

In other news, insider Michele Holcomb bought 93,944 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were acquired at an average cost of GBX 1 per share, with a total value of £939.44. Also, insider John LaMattina purchased 93,944 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was purchased at an average cost of GBX 1 per share, with a total value of £939.44. Insiders have purchased 617,569 shares of company stock valued at $18,063,751 in the last quarter. 13.41% of the stock is currently owned by insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.